<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030211</url>
  </required_header>
  <id_info>
    <org_study_id>TTSH ADEPT</org_study_id>
    <nct_id>NCT01030211</nct_id>
  </id_info>
  <brief_title>Adult Dengue Platelet Study</brief_title>
  <acronym>ADEPT</acronym>
  <official_title>Adult Dengue Platelet Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective data in children with dengue hemorrhagic fever (DHF) and dengue shock syndrome&#xD;
      (DSS), and in adults with dengue fever (DF), suggested a lack of benefit from prophylactic&#xD;
      platelet transfusion for severe thrombocytopenia in dengue patients without bleeding.&#xD;
      However, in Taiwan and Singapore, platelet transfusion was given to 13-50% of hospitalised&#xD;
      dengue patients. This is a prospective randomised study to examine the safety and efficacy of&#xD;
      prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without&#xD;
      bleeding.&#xD;
&#xD;
      The hypotheses are:&#xD;
&#xD;
        1. Prophylactic platelet transfusion is safe in hospitalised dengue patients with severe&#xD;
           thrombocytopenia.&#xD;
&#xD;
        2. Prophylactic platelet transfusion is effective in preventing bleeding in hospitalised&#xD;
           dengue patients with severe thrombocytopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling inclusion and exclusion criteria, and giving informed consent, will be&#xD;
      randomised to a treatment arm of 4 units of platelets for every day they have a platelet&#xD;
      count &lt;20x10^3/uL, or a control arm with supportive care. Patients will be followed up daily&#xD;
      till hospital discharge, and again at day 21.&#xD;
&#xD;
      It is assumed that the incidence of bleeding from randomization to Day 7 or discharge,&#xD;
      whichever earlier, is 10% for the control (no transfusion) group and 5% for the intervention&#xD;
      (transfusion) group. With 1:1 allocation ratio, to attain 80% power and one-sided 5% type I&#xD;
      error rate, the required number of subjects in each arm is 382 by a Chi-square test with&#xD;
      Yates' continuity correction. If a drop-out rate of 5% is allowed, the required number&#xD;
      increases to approximately 400 per arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical bleeding excluding petechiae with a subgroup analysis for severe clinical bleeding.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet increment post-transfusion</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet &gt; 50 x 10^3/uL</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokines</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leakage</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHF/DSS</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary bacterial infection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events from transfusion</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Platelet transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 units of platelets for patients with platelet count &lt;20x10^3/uL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No platelet transfusion for patients with platelet count &lt;20x10^3/uL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet transfusion</intervention_name>
    <description>4 units of platelets for patients with platelet count &lt;20x10^3/uL</description>
    <arm_group_label>Platelet transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive care</intervention_name>
    <description>Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure</description>
    <arm_group_label>Supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 21years&#xD;
&#xD;
          2. Probable or confirmed dengue&#xD;
&#xD;
             a) Confirmed dengue: laboratory confirmation of acute dengue by either i) positive&#xD;
             polymerase chain reaction (PCR) for viral ribonucleic acid (RNA), or ii)positive NS1&#xD;
             antigen test with a compatible clinical syndrome b) Probable dengue: Positive acute&#xD;
             dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 criteria&#xD;
             for probable dengue.&#xD;
&#xD;
             i) 1997 criteria: Acute febrile illness and two or more of the following:&#xD;
&#xD;
               -  headache,&#xD;
&#xD;
               -  retro-orbital pain,&#xD;
&#xD;
               -  myalgia,&#xD;
&#xD;
               -  arthralgia,&#xD;
&#xD;
               -  rash,&#xD;
&#xD;
               -  hemorrhagic manifestations,&#xD;
&#xD;
               -  leucopoenia ii) 2009 criteria: Fever and two of the following:&#xD;
&#xD;
               -  nausea/vomiting,&#xD;
&#xD;
               -  rash,&#xD;
&#xD;
               -  aches/pains,&#xD;
&#xD;
               -  positive tourniquet test,&#xD;
&#xD;
               -  leucopoenia,&#xD;
&#xD;
               -  one or more warning sign&#xD;
&#xD;
               -  abdominal pain/tenderness,&#xD;
&#xD;
               -  persistent vomiting,&#xD;
&#xD;
               -  clinical fluid accumulation,&#xD;
&#xD;
               -  mucosal bleed,&#xD;
&#xD;
               -  lethargy/restlessness,&#xD;
&#xD;
               -  liver enlargement &gt;2cm,&#xD;
&#xD;
               -  increase in haematocrit concurrent with rapid decrease in platelet count&#xD;
&#xD;
          3. Platelets ≤ 20x103/μL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee S Leo, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tan Tock Seng Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital, National University Health System, Singapore General Hospital, Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <last_update_submitted>August 23, 2015</last_update_submitted>
  <last_update_submitted_qc>August 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tan Tock Seng Hospital</investigator_affiliation>
    <investigator_full_name>David Lye</investigator_full_name>
    <investigator_title>Dr David Lye</investigator_title>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Platelet transfusion</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

